NeuroStar TMS Therapy® — Remission From Depression Is Possible

NeuroStar TMS Therapy consistently demonstrated significant response and remission rates in a difficult to treat population5,6:

  • 1 in 2 patients responded to treatment
  • 1 in 3 patients achieved remission

Backed by the largest clinical data set of any TMS Therapy in depression with 6 studies completed with 800 patients:

  • Two multisite, randomized controlled trials demonstrated clinically significant antidepressant effect of TMS7,8
  • Two open-label extension studies demonstrated consistent results5,9
  • One prospective, naturalistic study confirmed results in real-world practice6
  • One open-label, long-term, follow-up study demonstrated safety10

NeuroStar TMS Therapy offers:

Clinical results: Improvement in depression symptoms

  • In a difficult to treat population, patients treated with NeuroStar TMS Therapy received greater than 3 times the improvement in depressive symptoms compared to placebo at 4 weeks (MADRS, -7.1 vs -2.1, P=0.0006)5
  • Statistical significance in favor of active NeuroStar TMS Therapy was observed as early as 2 weeks after treatment and at 4 and 6 weeks (P=0.0006)5

NeuroStar® Randomized Controlled Trial Key Outcome Measure (Indicated Population) – Change Score in Montgomery-Asberg Depression Rating Scale (MADRS)5

NeuroStar depression rating scale results

In a randomized, placebo-controlled study, patients with DSM-IV Major Depressive Disorder experiencing moderate to severe symptoms at baseline received either NeuroStar TMS Therapy or sham TMS. Patients had received an average of 4 antidepressant medication attempts in current episode (range of 1 to 23 attempts) without success due to intolerance.5

Clinical results: Significant response and remission rates demonstrated

Patients treated with NeuroStar TMS Therapy experienced significant benefits after 4 to 6 weeks of treatment5,6:

NeuroStar end of acute treatment outcomes

A multicenter study including 307 (acute phase) evaluable unipolar, non-psychotic MDD patients in post-market use were evaluated after treatment with NeuroStar TMS Therapy.

View NeuroStar TMS Therapy Safety Data

Ongoing NeuroStar® Clinical Trials

Neuronetics continues to support clinical trial programs. The following are sponsored by Neuronetics:

  • Maintenance of Effect – This pilot study will evaluate post-acute treatment success and whether or not a monthly maintenance treatment with NeuroStar TMS will decrease the time to re-introduction of another acute course of treatment. This study is currently enrolling patients through September 2013. For more information please contact a Primary Investigator near you:
Primary Investigator Location Phone
Or visit for study NCT01415154.
Mark George, MD Medical University
of South Carolina
Charleston, SC
David Dunner, MD Center for Anxiety
and Depression
Mercer Island, WA
Sheila Dowd, PhD Rush University
Medical Center
Chicago, IL
Noah Phillip, MD Butler Hospital
Providence, RI
Scott Aaronson, MD Sheppard Pratt
Health System
Baltimore, MD
Walter Duffy, MD Premier Psychiatric
Group, LLC
Lincoln, NE
  • Postpartum study – TMS Therapy is already approved for Major Depressive Disorder. This study will focus on understanding the response in women suffering from postpartum depression. This study is currently enrolling patients who are:
    • Female 18 to 50
    • Diagnosed with major depression within 6 months of childbirth

For more information, contact Customer Service at 1-877-600-7555 (opt 3) or visit, for study NCT01842542.

Other studies using NeuroStar/Neuronetics devices

To learn more about clinical trials or search for other TMS studies, please visit

If you are interested in conducting an Investigator Initiated Trial, please contact Neuronetics Customer Service at 1-877-600-7555 (opt 3).